Kura Oncology to Participate in Three Upcoming Investor Conferences
26 mai 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2022 Financial Results
04 mai 2022 16h05 HE
|
Kura Oncology, Inc.
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in...
Kura Oncology to Report First Quarter 2022 Financial Results
27 avr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
08 avr. 2022 13h00 HE
|
Kura Oncology, Inc.
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – –...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
08 mars 2022 17h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
28 févr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h03 HE
|
Kura Oncology, Inc.
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase...
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
17 févr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
10 févr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Expands Leadership Team with Key Promotions
01 févr. 2022 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...